Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accredited, adagrasib, adaptive, Addendum, affinity, AI, Amgen, antiangiogenic, appointed, arbitration, Asia, Australia, authentication, automated, axitinib, azacitidine, backbone, backstopped, bear, begun, biochemical, bona, Brian, Cabomeyx, cabozantinib, ccRCC, CDX, censored, chosen, comer, comment, COO, copy, correct, corrective, crystal, cycle, darkweb, deceptive, deepen, degradation, dehydrogenase, delete, deposit, depth, DoR, Draft, durvalumab, EHA, Eisai, email, enasidenib, fake, FDIC, fide, fludarabine, Frankfurt, Germany, harvesting, HCT, hematopoietic, honor, hosted, hosting, idarubicin, IDHIFA, illustrated, Imfinzi, infer, Inlyta, innate, intelligence, Interagency, ipilimumab, IRF, isocitrate, ivosidenib, Krazati, leaked, led, lenvatinib, Lenvima, LeukemiaNet, Libtayo, LLS, manual, Middle, Mirati, misrepresentative, monumental, mTOR, myelosuppression, NE, nonstatutory, olutasidenib, oncogenetic, outlining, outperform, physical, Powl, prognostic, provincial, quizartinib, rational, RCC, reactivation, receivership, Recoupment, refundable, Regeneron, regular, relocate, Republic, retaliatory, revumenib, REZLIDHIA, Rigel, RYDAPT, Servier, Silvergate, SIP, sotorasib, stable, sterling, stricter, subscribing, Summit, synergy, TIBSOVO, tighter, TKI, undergone, undermine, unfair, Utrecht, VAF, VANFLYTA, wiretapping, XOSPATA, Yervoy
Removed:
adult, ALG, Bristol, Cambridge, caring, comparative, consult, contingency, Cyramza, dialog, digestive, epidermal, Epizyme, FCPA, FTE, fulfil, Grasso, hospital, HPV, immune, interact, investigative, Lilly, Marc, movement, negotiated, nondeductible, outbreak, outpatient, oversee, pace, paused, PFS, precaution, precautionary, proceed, propose, qPCR, quarantined, ramucirumab, remotely, risky, routine, safely, secondary, sequester, slowdown, startup, Stein, Steven, Stifel, sublease, subleased, subsidiary, sum, timeline, tract, unenforceability, upper, verifiable, verification, verify, Wellspring
Filing tables
Filing exhibits
Related press release
KURA similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
1.
Registration Statement (Form S-3 Nos. 333-275279 and 333-276995) of Kura Oncology, Inc.,
2.
Registration Statement (Form S-8 Nos. 333-203504, 333-210260 and 333-263000) pertaining to the Amended and Restated 2014 Equity Incentive Plan and the 2015 Employee Stock Purchase Plan of Kura Oncology, Inc., and
3.
Registration Statement (Form S-8 Nos. 333-216683, 333-223591, 333-230075, 333-236621, 333-253441, 333-269974 and 333-272389) pertaining to the Amended and Restated 2014 Equity Incentive Plan of Kura Oncology, Inc.;
of our reports dated February 27, 2024, with respect to the financial statements of Kura Oncology, Inc. and the effectiveness of internal control over financial reporting of Kura Oncology, Inc. included in this Annual Report (Form 10-K) of Kura Oncology, Inc. for the year ended December 31, 2023.
/s/ Ernst & Young LLP
San Diego, California
February 27, 2024